Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
2QG1 is a Phase IIa study aiming to assess the blood pressure lowering effect of 4-week
administration of QGC001 oral doses in patients with grade I or II essential hypertension
compared to placebo, to assess the safety and tolerability, to obtain preliminary PK
information for QGC001 given as multiple oral doses and to determine preliminary PD profile
of QGC001 multiple oral doses on plasma and urine hormones, which will be compared to that of
placebo.